ME02312B - DERIVATI PIRAZOLOSPIROKETONA, NAMIJENJENI UPOTREBI KAO INHIBITORI ACETIL-CoA-KARBOKSILAZE - Google Patents
DERIVATI PIRAZOLOSPIROKETONA, NAMIJENJENI UPOTREBI KAO INHIBITORI ACETIL-CoA-KARBOKSILAZEInfo
- Publication number
- ME02312B ME02312B MEP-2015-214A MEP2015214A ME02312B ME 02312 B ME02312 B ME 02312B ME P2015214 A MEP2015214 A ME P2015214A ME 02312 B ME02312 B ME 02312B
- Authority
- ME
- Montenegro
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- acetyl
- coa carboxylase
- pyrazolospiroketone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
- Photographic Processing Devices Using Wet Methods (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Peptides Or Proteins (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (5)
1. Spoj, naznačen time što je spoj Formule (I) , ili njegova farmaceutski prihvatljiva sol.
2. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s patentnim zahtjevom 1, ili njegovu farmaceutski prihvatljivu sol, kao i farmaceutski prihvatljivu pomoćnu tvar, razrjeđivač ili podlogu.
3. Spoj u skladu s patentnim zahtjevom 1 ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u postupku liječenja bolesti, stanja ili poremećaja koje se modulira inhibiranjem jednog ili više enzima acetil-CoA karboksilaza.
4. Spoj u skladu s patentnim zahtjevom 1 ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u postupku u skladu s patentnim zahtjevom 3, gdje je bolest, stanje ili poremećaj dijabetes tip 2, poremećaji povezani s dijabetesom, nealkoholna bolest masne jetre (NAFLD) ili jetrena otpornost na inzulin.
5. Spoj u skladu s patentnim zahtjevom 1 ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u postupku u skladu s patentnim zahtjevom 3, gdje je bolest, stanje ili poremećaj dijabetes tip 2.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161478240P | 2011-04-22 | 2011-04-22 | |
| EP12718387.9A EP2699576B1 (en) | 2011-04-22 | 2012-04-09 | Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors |
| PCT/IB2012/051732 WO2012143813A1 (en) | 2011-04-22 | 2012-04-09 | Pyrazolospiroketone derivatives for use as acetyl - coa carboxylase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02312B true ME02312B (me) | 2016-06-20 |
Family
ID=46025823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-214A ME02312B (me) | 2011-04-22 | 2012-04-09 | DERIVATI PIRAZOLOSPIROKETONA, NAMIJENJENI UPOTREBI KAO INHIBITORI ACETIL-CoA-KARBOKSILAZE |
Country Status (43)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102695708B (zh) * | 2009-11-10 | 2014-10-15 | 辉瑞大药厂 | N1-吡唑并螺酮乙酰辅酶a羧化酶抑制剂 |
| CN102491974B (zh) * | 2011-12-12 | 2013-08-07 | 南京药石药物研发有限公司 | 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法 |
| KR102243637B1 (ko) | 2013-03-14 | 2021-04-26 | 리커리엄 아이피 홀딩스, 엘엘씨 | 바이사이클릭 진통 화합물 |
| HK1221662A1 (zh) | 2013-05-10 | 2017-06-09 | Gilead Apollo, Llc | Acc抑制剂和其用途 |
| MX2015015422A (es) | 2013-05-10 | 2016-06-21 | Nimbus Apollo Inc | Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos. |
| CN105358152A (zh) * | 2013-05-10 | 2016-02-24 | 尼普斯阿波罗有限公司 | Acc抑制剂和其用途 |
| BR112016004118A2 (pt) | 2013-09-12 | 2017-10-17 | Pfizer | uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar |
| JPWO2015056782A1 (ja) | 2013-10-17 | 2017-03-09 | 塩野義製薬株式会社 | 新規アルキレン誘導体 |
| EP3080072A4 (en) * | 2013-12-12 | 2017-07-19 | Kalyra Pharmaceuticals, inc. | Bicyclic alkyl compounds and synthesis |
| WO2015134710A1 (en) * | 2014-03-07 | 2015-09-11 | Kalyra Pharmaceuticals, Inc. | Propellane derivates and synthesis |
| CA2892342C (en) | 2014-05-22 | 2016-11-01 | Sylvain-Paul Morency | Tool and method for layer depalletizing |
| WO2016044331A1 (en) | 2014-09-17 | 2016-03-24 | Kalyra Pharmaceuticals, Inc. | Bicyclic compounds |
| HK1255689A1 (en) * | 2015-12-31 | 2019-08-23 | 北京谷神生命健康科技有限公司 | Triacetyl-3-hydroxyphenyladenosine and application in preparing pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease |
| CN106580986B (zh) * | 2016-11-28 | 2017-09-15 | 王保亮 | 一种治疗少弱精子症的药物组合物 |
| MX389668B (es) | 2017-05-15 | 2025-03-20 | Recurium Ip Holdings Llc | Compuestos biciclo[1.1.1]pentilo sustituidos y uso de los mismos para el tratamiento del dolor y fiebre. |
| IL313710A (en) | 2017-11-21 | 2024-08-01 | Pfizer | Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid |
| CN111574530B (zh) * | 2020-04-21 | 2022-07-26 | 徐州医科大学 | 一种acc抑制剂及其医药用途 |
| CN120457124A (zh) * | 2022-12-30 | 2025-08-08 | 苏州浦合医药科技有限公司 | Prmt5-mta抑制剂 |
| CN121241054A (zh) * | 2023-04-14 | 2025-12-30 | 北京双鹤润创科技有限公司 | 氮杂环羰基稠环衍生物及其用途 |
| WO2025036472A1 (en) * | 2023-08-16 | 2025-02-20 | Pharmaengine, Inc. | Spirocyclic mta-cooperative prmts inhibitor |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69837903T2 (de) | 1997-08-11 | 2008-02-14 | Pfizer Products Inc., Groton | Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit |
| JP4104983B2 (ja) | 2001-02-28 | 2008-06-18 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−４受容体作動薬としてのアシル化ピペリジン誘導体 |
| EP1478437B1 (en) | 2002-02-27 | 2005-08-31 | Pfizer Products Inc. | Acc inhibitors |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| WO2004092179A1 (ja) | 2003-04-14 | 2004-10-28 | Nippon Soda Co. Ltd. | スピロ誘導体、製造法および抗酸化薬 |
| JP2005119987A (ja) | 2003-10-15 | 2005-05-12 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
| BRPI0510284A (pt) | 2004-05-12 | 2007-10-30 | Pfizer Prod Inc | derivados de prolina e seu uso como inibidores da dipeptidil peptidase iv |
| US20050267221A1 (en) | 2004-05-14 | 2005-12-01 | Research Development Foundation | Use of curcumin and analogues thereof as inhibitors of ACC2 |
| AP2006003768A0 (en) | 2004-05-25 | 2006-10-31 | Pfizer Prod Inc | TetraazabenzoÄeÜazulene derivatives and analogs tehereof |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| BRPI0613427A2 (pt) | 2005-07-19 | 2012-10-30 | Merck & Co Inc | composto ou seu sal ou éster, composição farmacêutica, agente terapêutico, e , uso do composto ou seu sal ou éster |
| US20100160255A1 (en) | 2005-07-29 | 2010-06-24 | Takeda Pharmaceutical Company Limited | Spiro-cyclic compound |
| DE602006019304D1 (de) | 2005-11-18 | 2011-02-10 | Merck Sharp & Dohme | Spirohydantoin-aryl-cgrp-rezeptorantagonisten |
| JP2009526868A (ja) | 2006-02-15 | 2009-07-23 | アボット・ラボラトリーズ | 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用 |
| ES2487967T3 (es) | 2006-04-20 | 2014-08-25 | Pfizer Products Inc. | Compuestos amido heterocíclicos condensados con fenilo para la prevención y el tratamiento de enfermedades mediadas por la glucoquinasa |
| AU2007326950B2 (en) | 2006-11-29 | 2010-10-14 | Pfizer Products Inc. | Spiroketone acetyl-CoA carboxylase inhibitors |
| PE20081559A1 (es) | 2007-01-12 | 2008-11-20 | Merck & Co Inc | DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA |
| JPWO2008102749A1 (ja) * | 2007-02-20 | 2010-05-27 | 武田薬品工業株式会社 | 複素環化合物 |
| CA2683695C (en) | 2007-04-12 | 2013-06-18 | Pfizer Inc. | 3-amido-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| US7981904B2 (en) | 2008-03-20 | 2011-07-19 | Takeda Pharmaceutical Company Limited | Acetyl CoA carboxylase inhibitors |
| US8318762B2 (en) | 2008-05-28 | 2012-11-27 | Pfizer Inc. | Pyrazolospiroketone acetyl-CoA carboxylase inhibitors |
| WO2009144555A1 (en) | 2008-05-28 | 2009-12-03 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| JP5501256B2 (ja) * | 2008-07-04 | 2014-05-21 | Ｍｓｄ株式会社 | 新規スピロクロマノンカルボン酸 |
| EP2310015A4 (en) | 2008-07-14 | 2011-10-26 | Cropsolution Inc | ACETYL-COENZYME-CARBOXYLASE MODULATORS AND METHODS OF USE THEREOF |
| US20110130365A1 (en) | 2008-07-29 | 2011-06-02 | Benbow John W | Fluorinated Heteroaryls |
| AP2728A (en) | 2008-08-28 | 2013-08-31 | Pfizer | Dioxa-bicyclo[3.2.1.] octane-2,3,4-triol derivatives |
| WO2010086820A1 (en) | 2009-02-02 | 2010-08-05 | Pfizer Inc. | 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof |
| CA2754685A1 (en) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Substituted indazole amides |
| DK2406253T3 (da) | 2009-03-11 | 2013-08-12 | Pfizer | Benzofuranylderivater anvendt som glucokinase-inhibitorer |
| EP2408780A2 (en) | 2009-03-20 | 2012-01-25 | Pfizer Inc. | 3-oxa-7-azabicycloý3.3.1¨nonanes |
| US20120052130A1 (en) | 2009-05-08 | 2012-03-01 | Pfizer Inc. | Gpr 119 modulators |
| CA2759843A1 (en) | 2009-05-08 | 2010-11-10 | Pfizer Inc. | Gpr 119 modulators |
| AP2799A (en) | 2009-06-05 | 2013-11-30 | Pfizer | 1-(Piperidin-4-YL)-pyrazole derivatives as GPR 119modulators |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
| CN102695708B (zh) * | 2009-11-10 | 2014-10-15 | 辉瑞大药厂 | N1-吡唑并螺酮乙酰辅酶a羧化酶抑制剂 |
| US20120225900A1 (en) * | 2009-11-10 | 2012-09-06 | Pfizer Inc. | N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| RS55224B1 (sr) * | 2010-09-30 | 2017-02-28 | Pfizer | N1-pirazolospiroketon acetil-coa karboksilaza inhibitori |
-
2012
- 2012-04-09 RS RS20160026A patent/RS54526B1/sr unknown
- 2012-04-09 MY MYPI2013003372A patent/MY162167A/en unknown
- 2012-04-09 WO PCT/IB2012/051732 patent/WO2012143813A1/en not_active Ceased
- 2012-04-09 JP JP2014505745A patent/JP5657174B2/ja active Active
- 2012-04-09 PL PL12718387T patent/PL2699576T3/pl unknown
- 2012-04-09 SG SG2013075148A patent/SG194142A1/en unknown
- 2012-04-09 CN CN201610487378.8A patent/CN106117205B/zh not_active Expired - Fee Related
- 2012-04-09 GE GEAP201213267A patent/GEP20166474B/en unknown
- 2012-04-09 SI SI201230417T patent/SI2699576T1/sl unknown
- 2012-04-09 HR HRP20151397TT patent/HRP20151397T1/hr unknown
- 2012-04-09 AU AU2012245996A patent/AU2012245996B2/en not_active Ceased
- 2012-04-09 DK DK12718387.9T patent/DK2699576T3/en active
- 2012-04-09 ME MEP-2015-214A patent/ME02312B/me unknown
- 2012-04-09 CA CA2831380A patent/CA2831380C/en active Active
- 2012-04-09 PH PH1/2013/501941A patent/PH12013501941A1/en unknown
- 2012-04-09 CN CN201280019621.3A patent/CN103492388A/zh active Pending
- 2012-04-09 ES ES12718387.9T patent/ES2561452T3/es active Active
- 2012-04-09 EP EP12718387.9A patent/EP2699576B1/en active Active
- 2012-04-09 PT PT127183879T patent/PT2699576E/pt unknown
- 2012-04-09 AP AP2013007129A patent/AP3499A/xx active
- 2012-04-09 CU CU20130126A patent/CU24164B1/es active IP Right Grant
- 2012-04-09 HU HUE12718387A patent/HUE028602T2/hu unknown
- 2012-04-09 KR KR1020137030875A patent/KR101567659B1/ko not_active Expired - Fee Related
- 2012-04-09 EA EA201391288A patent/EA022375B1/ru not_active IP Right Cessation
- 2012-04-09 PE PE2013002387A patent/PE20141187A1/es not_active Application Discontinuation
- 2012-04-09 MA MA36357A patent/MA35061B1/fr unknown
- 2012-04-09 MX MX2013012313A patent/MX348860B/es active IP Right Grant
- 2012-04-09 NZ NZ616156A patent/NZ616156A/en not_active IP Right Cessation
- 2012-04-18 TW TW101113766A patent/TWI464171B/zh not_active IP Right Cessation
- 2012-04-19 UY UY0001034027A patent/UY34027A/es not_active Application Discontinuation
- 2012-04-20 PY PY201201218709A patent/PY1218709A/es unknown
- 2012-04-20 AR ARP120101364A patent/AR086198A1/es unknown
- 2012-04-21 US US13/452,839 patent/US8802688B2/en active Active
- 2012-09-04 UA UAA201311822A patent/UA107753C2/ru unknown
-
2013
- 2013-09-12 CR CR20130464A patent/CR20130464A/es unknown
- 2013-09-27 CL CL2013002794A patent/CL2013002794A1/es unknown
- 2013-09-27 TN TNP2013000393A patent/TN2013000393A1/fr unknown
- 2013-10-17 IL IL228949A patent/IL228949A/en active IP Right Grant
- 2013-10-18 NI NI201300111A patent/NI201300111A/es unknown
- 2013-10-18 GT GT201300258A patent/GT201300258A/es unknown
- 2013-10-21 DO DO2013000243A patent/DOP2013000243A/es unknown
- 2013-10-24 CO CO13252716A patent/CO6801757A2/es active IP Right Grant
- 2013-11-22 EC ECSP13013038 patent/ECSP13013038A/es unknown
-
2014
- 2014-07-08 US US14/325,420 patent/US20140323730A1/en not_active Abandoned
-
2015
- 2015-01-09 US US14/593,370 patent/US20150112068A1/en not_active Abandoned
- 2015-08-07 US US14/820,884 patent/US20150336958A1/en not_active Abandoned
-
2016
- 2016-01-14 CY CY20161100038T patent/CY1117122T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02312B (me) | DERIVATI PIRAZOLOSPIROKETONA, NAMIJENJENI UPOTREBI KAO INHIBITORI ACETIL-CoA-KARBOKSILAZE | |
| ME02182B (me) | TERAPEUTSKA KOMBINACIJA KOJA SADRŽI DOLUTEGRAVIR, ABAKAVIR l LAMIVUDIN | |
| BR112014003225A2 (pt) | profármacos de treprostinil ligados a veículo | |
| MX2016000307A (es) | Farmaco para el tratamiento de la esteatosis hepatica no alcoholica. | |
| HRP20171512T1 (hr) | Derivati betulina | |
| NZ609527A (en) | N1/n2-lactam acetyl-coa carboxylase inhibitors | |
| ECSP13012668A (es) | Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso | |
| BR112015000106A2 (pt) | moduladores heterocíclicos de síntes de lipídio | |
| GEP20166483B (en) | Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament | |
| WO2012162254A8 (en) | Inhibitors of lrrk2 kinase activity | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| WO2012094598A3 (en) | Pharmaceutical compositions of iron for oral administration | |
| BR112015010707A2 (pt) | derivados de 5-flúor-n-(piridin-2-il)piridin-2-amina contendo um grupo sulfoximina | |
| EA201400067A1 (ru) | Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента | |
| BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
| HRP20160203T1 (hr) | Pripravci koji sadrže 15-hepe i postupci njihove upotrebe | |
| WO2012048129A3 (en) | Inhibitors of polo-like kinase | |
| EA201300990A1 (ru) | Парентеральное введение тапентадола | |
| JO3263B1 (ar) | مشتق إندان سلفاميد جديد | |
| BR112015010136A2 (pt) | derivados de oxazolidin-2-ona-pirimidina | |
| HK1219222A1 (zh) | 包含降血脂药的制剂 | |
| ME02405B (me) | Spojevi pirazola као inhibitori sglt1 | |
| CA2922375C (en) | Alpha-tea salt forms: compositions and uses for treating disease | |
| EA201270653A1 (ru) | Антагонист dpи его применение | |
| EP2722322A4 (en) | 1,3-DI-OXO-INDEN DERIVATIVE, PHARMACEUTICALLY ALLOWED SALT AND OPTICAL ISOMER THEREOF, METHOD OF MANUFACTURING THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THIS DERIVATIVE AS AN ANTIVIRAL ACTIVE SUBSTANCE |